Harvard Bioscience (HBIO) Gross Margin (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Gross Margin of 58.99% for Q1 2026, up 304.0% year-over-year from 14.6% in Q1 2025, and down 1.2% quarter-over-quarter from 59.71% in Q4 2025.
Harvard Bioscience (HBIO) Gross Margin (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Gross Margin for 17 consecutive years, with 58.99% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin rose 304.0% year-over-year to 58.99%; the TTM figure through Mar 2026 stood at 58.42% (up 133.0% YoY), while the FY2025 annual figure was 57.67%, down 51.0% from the prior year.
- Gross Margin declined to 58.99% in Q1 2026 per HBIO's latest filing, from 59.71% in the prior quarter.
- Across five years, Gross Margin topped out at 61.2% in Q1 2023 and bottomed at 45.21% in Q3 2022.
- Historically, Gross Margin has averaged 57.14% across 5 years, with a median of 57.97% in 2023.
- Annual changes were most pronounced in 2022 — Gross Margin tumbled 977 bps — and 2023, when it soared 1285 bps.
- Harvard Bioscience's Gross Margin stood at 55.7% in 2022, then advanced by 4 bps to 57.99% in 2023, then declined by 2 bps to 57.06% in 2024, then rose by 5 bps to 59.71% in 2025, then declined by 1 bps to 58.99% in 2026.
- Business Quant data shows HBIO's Gross Margin at 58.99% in Q1 2026, 59.71% in Q4 2025, and 58.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.89 Bn | 127.67 Bn | 1.96 Bn | 67.78% |
| 2 | Becton Dickinson | 51.87 Bn | 51.01 Bn | 2.32 Bn | 46.46% |
| 3 | Alcon | 35.51 Bn | 34.16 Bn | 1.68 Bn | 59.33% |
| 4 | Resmed | 33.52 Bn | 32.06 Bn | 861.22 Mn | 58.84% |
| 5 | Medline | 28.31 Bn | 25.63 Bn | 2.22 Bn | 28.82% |
| 6 | West Pharmaceutical Services | 24.97 Bn | 24.53 Bn | 329.20 Mn | 37.74% |
| 7 | Solventum | 15.26 Bn | 14.86 Bn | 1.29 Bn | 58.22% |
| 8 | Cooper Companies | 14.84 Bn | 14.70 Bn | 735.40 Mn | 68.00% |
| 9 | Baxter International | 13.57 Bn | 11.42 Bn | 1.03 Bn | 34.86% |
| 10 | Harvard Bioscience | 34.35 Mn | 27.85 Mn | 12.63 Mn | 55.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.57% |
| Mar 31, 2026 | 58.99% |
| Dec 31, 2025 | 59.71% |
| Sep 30, 2025 | 58.38% |
| Jun 30, 2025 | 56.40% |
| Mar 31, 2025 | 55.96% |
| Dec 31, 2024 | 57.06% |
| Sep 30, 2024 | 58.10% |
| Jun 30, 2024 | 57.23% |
| Mar 31, 2024 | 60.26% |
| Dec 31, 2023 | 57.99% |
| Sep 30, 2023 | 58.06% |
| Jun 30, 2023 | 57.97% |
| Mar 31, 2023 | 61.20% |
| Dec 31, 2022 | 55.70% |
| Sep 30, 2022 | 45.21% |
| Jun 30, 2022 | 56.96% |
| Mar 31, 2022 | 56.21% |
| Dec 31, 2021 | 59.17% |
| Sep 30, 2021 | 54.98% |